In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...
We have revised our model following a soft 1Q25 performance in Radiology Solutions, contrasted by continued strong momentum in Agfa's HealthCare IT division—fuelled by growing customer adoption of its cloud-based technologies. While the Digital Printing Solutions equipment segment faced headwinds from ongoing economic uncertainty, and demand for Agfa's Zirfon membranes for green hydrogen production slowed in Europe and North America, the company maintains a positive long-term outlook for both bu...
1M Performance - Absolute: During May'25 (1M period), the KBCS Holdings Universe posted a return of +2.2% which was mainly driven by multi-asset holdings (+2.6%) while single-asset holdings posted a smaller return of +1.2%. The 3 top performers during the period were Gimv (+12.1%), KBC Ancora (+11.1%) and Ackermans & van Haaren (+4.1%) while the 3 worst performers were Solvac (-2.8%), Groupe Bruxelles Lambert (-0.8%) and Heineken Holding (-0.3%). YTD Performance - Relative: On a YTD basis (as o...
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
Aedifica and Cofinimmo: Agreement reached to create Europe's leading Healthcare REIT. bpost: CMD press release; #Reshape 2029. D'Ieteren: Belgian new car registrations down 11.7% in May, VW down 13.5% Fugro: Meeting with CEO & IR; 2Q25 also has its challenges. UCB: Peer Moonlake held takeover talks with US Merck, FT reports
Following the CMD on May 14th, we have slightly tweaked our estimates for the different divisions. While the new 2024-2028 ambitions were broadly in line with our expectations, we welcome the reiteration of the strong underlying growth drivers and good 1Q25 results at Belron. As we estimate D'Ieteren to be trading at a 25e adj. FCFy (gs) before M&A of 6.0%, we believe these strong growth drivers are not yet reflected in D'Ieteren's share price. Moreover, we think the mid-single digit adj. EBIT C...
A director at D`ieteren Group bought 230 shares at 182.120EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Yesterday, D'Ieteren disclosed its new 2024-2028 ambitions during a CMD in London. In general, D'Ieteren's new ambitions were broadly in line with our expectations and reconfirm the structural growth trends of the recent years. We therefore do not expect major changes to css expectations. While the event did not contain any major surprises, we did get some extra colour on certain topics, with the key new elements summarized below. We further also welcome the solid 1Q25 results at Belron. As the ...
CM.com: CMD – AI-first strategy, new medium-term targets. CVC Capital Partners: Good realisations. D'Ieteren: CMD feedback. Euronext: An even stronger April is Next. Flow Traders: Promising April. KBC: M&A in Slovakia, capital changes, beat in 1Q. Prosus: iFood partners with Uber. SBM Offshore: FY25 starts reasonably well, decarbonization gains momentum. Syensqo: Modest 1Q25 beat, +€1.4bn FY EBITDA guidance excludes FX, tariff impact
1Q25 was marked by a weak performance in Radiology Solutions (1Q is traditionally a seasonally weak quarter but now with strong impact of the decline of the medical film markets, particularly in China) and the continued strong performance of Agfa's HealthCare IT division, driven by customer adoption of Agfa's cloud technology. While Agfa's Digital Printing Solutions equipment business faced challenges due to economic uncertainty, and the market for Agfa's Zirfon membranes for green hydrogen prod...
This morning D'Ieteren announced its new 2024-2028 ambitions which will be followed by a CMD in London later today. While the mid-single digit adj. EBIT growth target came below our estimate of 7.1%, we believe the outlook is rather prudent as the outlook for the different entities is almost perfectly in line with our expectations. No other major news was announced. While the 1Q25 sales update came in slightly below our estimates , we want to highlight that this was partially due to fewer tradi...
The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Regulated information May 14, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q1 2025: adjusted EBITDA stable versus Q1 2024 – improved mix and good cost control compensated for film market decline Group performance: continued success of the strategic transformation Improved sales mix between growth engines and mature businesses and good cost control compensated for the negative impact of the market ...
De Agfa-Gevaert Groep in het eerste kwartaal van 2025: aangepaste EBITDA stabiel tegenover eerste kwartaal van 2024 – verbeterde mix en goede kostcontrole compenseerde voor de achteruitgang van de filmmarkt Gereglementeerde informatie 14 mei 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het eerste kwartaal van 2025: aangepaste EBITDA stabiel tegenover eerste kwartaal van 2024 – verbeterde mix en goede kostcontrole compenseerde voor de achteruitgang van de filmmarkt Groepsprestatie: voortgezet succes van de strategische t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.